

## Hutchison China MediTech (Chi-Med)

FY18 results as expected, plentiful news flow in FY19

11 March 2019

- Chi-Med reported FY18 results that met or beat expectations. Group revenues were \$214.1m, down from \$241.2m as the two-invoice impacted how domestic China sales are reported, with the JV revenues growth of 13.4% to \$491.5m (from \$433.3m) being a better reflection of the Commercial Platform's performance. R&D spend in the Innovation Platform was \$142.2m, up from \$88.0m, as more later-stage clinical studies are undertaken. This sees the Group's attributable net loss rising to \$74.8m, against \$26.7m last year. Cash resources remained strong, with \$420.3m available at December 2018, versus \$479.6m in 2017.
- It is the Innovation Platform that is driving future growth, initially through addressing the China Oncology opportunity and further out Global Innovation. Elunate (fruquintinib) was the first domestically discovered and developed innovative compound approved in China. It was launched, together with Eli Lilly, in November and is showing solid early signs of clinical acceptance. The collaboration has been amended, with Chi-Med funding more clinical work in return for greater marketing freedom and better financials; this is likely to enact in 2021/2 in our opinion.
- Five products are currently in clinical trials aimed at Global markets, with clinical and regulatory teams being bolstered in the US and Europe. Four of these (fruquintinib, surufatinib, HMPL-523, and HMPL-689) are not partnered and will form the basis of the longer term global marketing infrastructure. Savolitinib is partnered with AstraZeneca and is on track to be approved in combination with Tagrisso by 2022, if not earlier, in our view. Management's target is to progress one novel drug candidate into global development per annum.
- 2019 is expected to see a wealth of news flow as a number of clinical studies produce both interim and mature results. The first of these is likely to be two presentations at the AACR meeting in 29 March-3 April, with the Phase II data of the savolitinib single agent NSCLC Exon 14 deletion study and the Phase Ib results for the savolitinib/Tagrisso combination in NSCLC (the TATTON study) scheduled. A further dozen trial results are likely to be presented at various conferences during the year.
- The guidance for 2019 is for R&D expenditure to be \$160-200m and adjusted net cash flows (non-GAAP) to be -\$120m to -\$150m.

**Trinity Delta view:** Chi-Med continues to perform to our expectations. The depth of the development pipeline means the coming year should see a steady stream of share price catalysts. Our valuation employs a DCF-based sum-of-the-parts approach, which includes a detailed rNPV model of the clinical pipeline. Our current valuation is \$4.5bn/£3.4bn, which is equivalent to \$33.49/ADS or £51.52/share.

Price (US ADS)	\$27.29
(UK share)	3,980p
Market Cap	\$3.51bn £2.79bn
Exchanges	NASDAQ AIM London
Sector	Healthcare
Company codes	HCM HCM.L
Corporate client	Yes

### Company description

Hutchison China MediTech is a Hong Kong headquartered biopharma with an established Commercial Platform in China, and a diverse pipeline of first-in-class/best-in-class selective oral tyrosine kinase inhibitors (Innovation Platform). Its pipeline, discovered in-house, is in development for the China and global oncology markets.

### Analysts

**Mick Cooper PhD**  
mcooper@trinitydelta.org  
+44 (0) 20 3637 5042

**Lala Gregorek**  
lgregorek@trinitydelta.org  
+44 (0) 20 3637 5043

**Mick Cooper PhD CFA**

[mcooper@trinitydelta.org](mailto:mcooper@trinitydelta.org)  
+44 20 3637 5042

**Lala Gregorek**

[lgregorek@trinitydelta.org](mailto:lgregorek@trinitydelta.org)  
+44 20 3637 5043

**Franc Gregori**

[fgregori@trinitydelta.org](mailto:fgregori@trinitydelta.org)  
+44 20 3637 5041

### Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at [www.fisma.org](http://www.fisma.org). TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2019 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: [www.trinitydelta.org](http://www.trinitydelta.org)